ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica."
Episode Synopsis
In this week's podcast, Neurology Today's editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer's, and a novel approach for managing uncomfortable neuropathic symptoms.
In God we trust